2VAN DER LINDEN S, VALKENBURG H A, CATS A. Evaluation of diagnostic criteria for ankylosing spondylitis. a proposal for modification of the New York criteria [J]. Arthritis Rheum, 1984, 27 (4): 361-368. 被引量：1
3DOUGADOS M, VAN DER LINDEN S, JUHLIN R, et al. The European Spondylarthropathy Study Group prelim- inary criteria for the classification of spondylarthropathy [J]. Arthritis Rheum, 1991, 34 (10): 1218-1227. 被引量：1
4RUDWALEIT M, VAN DER HEIJDE D, LANDEWE, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part Ⅱ) : validation and final selection [J]. Ann Rheum Dis, 2009, 68 (6): 777-783. 被引量：1
5ZOCHLING J, VAN DER HEIJDE D, DOUGADOS M, et al. Current evidence for the management of ankylosing spondylitis, a systematic literature review for the ASAS/ EULAR management recommendations in ankylosing spondylitis[J]. Ann Rheum Dis, 2006, 65(4) : 423-432. 被引量：1
3Bathon JM,Martin RW,Fleischmann RM,et al.A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.N Engl J Med,2000,343:1586-1593. 被引量：1
4Klareskog L,van der Heijde D,de Jager JP,et al.Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis:double-blind randomised controlled trial.Lancet,2004,363:675-681. 被引量：1
5Emery P,Breedveld FC,Hall S,et al.Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active,early,moderate to severe rheumatoid arthritis (COMET):a randomised,double-blind,parallel treatment trial.Lancet,2008,372:375-382. 被引量：1
6Rudwaleit M,van der Heijde D,Landewé R,et al.The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part Ⅱ):validation and final selection.Ann Rheum Dis,2009,68:777-783. 被引量：1
7Davis JC Jr,Van Der Heijde D,Braun j,et al.Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis:a randomized,controlled trial.Arthritis Rheum,2003,48:3230-3236. 被引量：1
8Davis JC Jr,van der Heijde DM,Braun J,et al.Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis.Ann Rheum Dis,2008,67:346-352. 被引量：1
9Dijkmans B,Emery P,Hakala M,et al.Etanercept in the longterm treatment of patients with ankylosing spondylitis.J Rheumatol,2009,36:1256-1264. 被引量：1
10van der Heijde D,Da Silva JC,Dougados M,et al.Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis.Ann Rheum Dis,2006,65:1572-1577. 被引量：1
